Home » Stocks » MRNA

Moderna, Inc. (MRNA)

Stock Price: $160.50 USD -2.34 (-1.44%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $161.50 +1.00 (0.62%) May 6, 5:51 PM
Market Cap 60.44B
Revenue (ttm) 803.40M
Net Income (ttm) -747.06M
Shares Out 381.33M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE 8.06
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $160.50
Previous Close $162.84
Change ($) -2.34
Change (%) -1.44%
Day's Open 147.82
Day's Range 143.56 - 163.47
Day's Volume 29,647,889
52-Week Range 46.13 - 189.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Why this biotech analyst has a hold rating on Moderna

YouTube video

CNBC's "Closing Bell" team discusses the biotech sector after Moderna reported its latest earnings results with Michael Yee of Jefferies.

2 hours ago - CNBC Television

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

5 hours ago - Zacks Investment Research

Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the estimate of $2.39.

5 hours ago - Benzinga

12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.

Other stocks mentioned: AREC, BKLLF, BLONF, GRSLF, HLRTF, MBII, NEXCF ...
5 hours ago - Proactive Investors

Is (MRNA) Outperforming Other Medical Stocks This Year?

6 hours ago - Zacks Investment Research

Moderna posts first-ever quarterly profit in Q1

YouTube video

Yahoo Finance's Anjalee Khemlani reports Moderna's first quarter and the outlook through 2021. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k

6 hours ago - Yahoo Finance

U.S. backs COVID-19 vaccine patent waiver

YouTube video

Yahoo Finance's Brian Sozzi, Myles Udland, Julie Hyman, and Anjalee Khemlani discuss what the vaccine patent waiver means for Moderna's business.

Other stocks mentioned: BNTX, JNJ, NVAX, PFE
7 hours ago - Yahoo Finance

Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.

Other stocks mentioned: NVAX, QURE
7 hours ago - Benzinga

Even bigger profits could be on the way, despite worries about international waivers of the biotech's patents for its COVID-19 vaccine.

7 hours ago - The Motley Fool

The US has backed a proposal first put forward by India and South Africa for a temporary waiver on COVID-19 vaccine patents. “The administration believes strongly in intellectual property protections, b...

Other stocks mentioned: PFE
7 hours ago - Proactive Investors

The shares of Moderna Inc (NASDAQ:MRNA) are careening this morning, down 10.3% to trade $146.03, and brushing off the company's first-ever profit.

8 hours ago - Schaeffers Research

Moderna (MRNA) delivered earnings and revenue surprises of 39.22% and -1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 hours ago - Zacks Investment Research

The drug manufacturer announced its first profitable first quarter.

8 hours ago - Forbes

Moderna CEO Stephane Bancel said Thursday the company expects more variants of the coronavirus will emerge in the coming months.

9 hours ago - CNBC

Moderna's (MRNA) Q1 earnings exceeded analyst expectations, while revenue missed estimates. It was the company's first profitable quarter.

9 hours ago - Investopedia

Moderna Inc (NASDAQ: MRNA) reports Q1 EPS of $2.84, a turnaround from EPS loss of $0.35 a year ago, beating the consensus estimate of $2.39. However, Q1 revenues of $1.9 billion compared to $8 million a...

10 hours ago - Benzinga

Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African ...

Other stocks mentioned: BNTX, PFE
10 hours ago - Proactive Investors

Moderna posts EPS beat, revenue miss for the first quarter

YouTube video

CNBC's Meg Tirrell reports on Moderna's first-quarter earnings results as well as the most recent data the company released about its Covid vaccine trials for teenagers.

10 hours ago - CNBC Television

Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation.

11 hours ago - Reuters

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna reports first quarter fiscal year 2021 financial results and provides business updates.

11 hours ago - Business Wire

The Biden administration is backing international plans to suspend intellectual property protections.

Other stocks mentioned: BNTX, PFE
11 hours ago - Forbes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with Switzerland for 7 million booster vaccine doses in 2022 and option for additional 7 million doses.

12 hours ago - Business Wire

Some of the stocks that may grab investor focus today are: Moderna Inc (NASDAQ: MRNA) reported the effectiveness of its COVID-19 vaccine against variants in an internal study. The company is also expect...

Other stocks mentioned: K, MCK, PYPL, ZNGA
13 hours ago - Benzinga

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Other stocks mentioned: BNTX, JNJ, PFE
20 hours ago - The Motley Fool

Two types of booster proved efficacious against a pair of more threatening coronavirus variants.

22 hours ago - The Motley Fool

Pharmaceutical stocks are facing a major new threat.

22 hours ago - The Motley Fool

Moderna releases new information on booster shots

YouTube video

Yahoo Finance's Anjalee Khemlani reports the latest update on Moderna's booster shot studies. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k

23 hours ago - Yahoo Finance

Moderna (MRNA) closed at $162.84 in the latest trading session, marking a -6.19% move from the prior day.

23 hours ago - Zacks Investment Research

Moderna Co-founder on Boosters Against Variant Strains

YouTube video

May.05 -- Moderna's mid-stage trials show its booster shots were effective against strains of the coronavirus that emerged from Brazil and South Africa. Co-founder Noubar Afeyan speaks exclusively with ...

1 day ago - Bloomberg Technology

Moderna said its booster dose increased neutralizing antibody responses against the original virus as well as B.1.351 and P.1 variants.

1 day ago - CNBC

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces positive initial booster data against SARS-CoV-2 variants of concern.

1 day ago - Business Wire

Moderna (MRNA) reports Q1 earnings before market open on May 6. Will the company finally report a profit after years of losses as COVID-19 vaccine sales soar?

1 day ago - Investopedia

Probably not, but the study could benefit another vaccine maker.

Other stocks mentioned: BNTX, PFE
1 day ago - The Motley Fool

Ocugen may be able to handle one of the biggest challenges facing vaccine makers.

Other stocks mentioned: OCGN, PFE
1 day ago - The Motley Fool

The biotech just provided a big clue that sales are poised to skyrocket.

1 day ago - The Motley Fool

Moderna to Supply 500 Million Covid-19 Vaccine Doses to Covax

YouTube video

May.04 -- Moderna co-founder and Chairman Noubar Afeyan discusses the company's agreement to provide 500 million doses of its Covid-19 vaccine to Covax, increased vaccine production, and testing of a lo...

2 days ago - Bloomberg Markets and Finance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces expansion of its Manufacturing Technology Center in Massachusetts.

2 days ago - Business Wire

They could be just getting started, too.

Other stocks mentioned: FB
2 days ago - The Motley Fool

Investors cheered the vaccine maker's latest move to help end the pandemic.

3 days ago - The Motley Fool

Final Trades: Uber, ViacomCBS, Moderna & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: UBER, VIAC, SGEN
3 days ago - CNBC Television

Wall Street Gears for a Hectic Earnings Week.

Other stocks mentioned: ADP, CNA, CVS, DO, EL, ETSY, GM ...
3 days ago - Zacks Investment Research

Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.

3 days ago - Zacks Investment Research

With Q1 earnings season continuing to unfold favorably (for the most part), investors look to enjoy a healthy Q2, as well.

Other stocks mentioned: ADP, CNA, CVS, DO, EL, ETSY, GM ...
3 days ago - Zacks Investment Research

Covax, the World Health Organization's vaccine sharing program, is in dire need of vaccine doses. Wealthier countries have faced calls to step up.

3 days ago - Forbes

Last Week – SPY closed slightly higher on the week but below its intra-week highs. The VIX closed higher on the week, up to 18.60 from 17.

Other stocks mentioned: CRON, DKNG, PTON, ROKU, UBER
3 days ago - Benzinga

In a crazy-good year for stocks, Robert Zedler, a 91-year-old retiree in Suffolk, Virginia, won Dorfman's Three-Stock Derby with a 334% return.

Other stocks mentioned: BHP, CPE, LMT, LTHM, PLUG, RIO
3 days ago - GuruFocus

Moderna Inc (NASDAQ: MRNA) has announced an agreement with vaccine promoter Gavi to supply up to 500 million doses of its COVID-19 vaccine to boost the global vaccination effort. Still, most of the ship...

3 days ago - Benzinga

They'll give us a snapshot of the future.

3 days ago - The Motley Fool

Both vaccines do an impressive job of providing protection against COVID-19. But Moderna's is much easier to get from production facilities into patients' arms.

Other stocks mentioned: BNTX, PFE
4 days ago - The Motley Fool

About MRNA

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeu... [Read more...]

Industry
Biotechnology
IPO Date
Dec 7, 2018
CEO
Stephane Bancel
Employees
1,300
Stock Exchange
NASDAQ
Ticker Symbol
MRNA
Full Company Profile

Financial Performance

In 2020, Moderna's revenue was $803.40 million, an increase of 1,234.34% compared to the previous year's $60.21 million. Losses were -$747.06 million, 45.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 175.50, which is an increase of 9.35% from the latest price.

Price Target
$175.50
(9.35% upside)
Analyst Consensus: Buy